#USA #Philadelphia #Field Medical #FieldForce #VT Symposium

Field Medical Innovations Revealed at VT Symposium 2025

Introduction
Field Medical, Inc., a trailblazer in the domain of pulsed field ablation (PFA) technology targeted at ventricular tachycardia (VT), recently announced its active participation in the esteemed VT Symposium 2025. This event is scheduled for October 10-11 in Philadelphia. During this symposium, the company is set to unveil its groundbreaking six-month data from its first-in-human clinical trial featuring the FieldForce™ Ablation System, a game-changing technology designed specifically for treating VT.

Presentations and Highlights

Field Medical will be featured in three significant sessions throughout the symposium, emphasizing new findings that underscore the potential of their technology. Among these presentations, Dr. Vivek Reddy will share insights derived from the “High-Voltage Focal Pulsed Field Ablation to Treat Scar-Related Ventricular Tachycardia.” This session, highlighting the final outcomes from the six-month clinical trial, underscores the advancements made in treating this challenging health situation.

The agenda includes another notable presentation by Dr. Cory Tschabrunn, who will be sharing findings from a porcine model related to chronic infarction. Additionally, a live demonstration titled “Image Guided High Voltage VT Ablation” will showcase real-world applications of the FieldForce™ system.

Commitment to Innovation

Mark Wisniewski, the Chairperson of Field Medical, expressed enthusiasm about presenting significant new data, stating, “The VT Symposium serves as a vital platform for advancing clinical science, and we are proud to share findings that reflect the urgent need for innovative solutions to support patients with VT.” He highlighted the six-month outcomes as a testament to the potential effectiveness of their PFA technology in addressing these complex arrhythmias.

Furthermore, as part of the company's strategic shift towards innovation, Steven Mickelsen, the founder and physician, has been appointed as the Chief Technology Officer. He will oversee clinical innovation and the ongoing development of the FieldForce™ Ablation System. Kit Schneider has stepped into the role of Chief Strategy Officer, focusing on long-term corporate strategy and growth partnerships.

Advancing Clinical Solutions

Field Medical, founded in 2022, is dedicated to the advancement of clinical solutions for complex cardiac arrhythmias through its innovative PFA technology. The FieldForce™ system is engineered to ensure effective and precise ablation, leveraging their proprietary FieldBending™ energy to treat both ventricular and atrial arrhythmias. With the 2024 Breakthrough Device Designation from the FDA, Field Medical is set to continue making strides in this area of healthcare, as they work tirelessly to enhance the quality of life for patients suffering from life-threatening arrhythmias.

Conclusion
The company's participation in the VT Symposium 2025 reflects its commitment to maintaining leadership in the medical technology field. Field Medical exemplifies how innovation can lead to improved patient outcomes and is determined to adapt to the dynamic landscape of cardiac treatment as it progresses. With detailed insights expected to emerge from their presentations, the future looks promising for patients dealing with ventricular tachycardia.

For more information about Field Medical and its innovative technologies, visit their official website at www.fieldmedicalinc.com.